ArticleTranslational andrology and urology2025
Genetically predicted benign prostate hyperplasia causally affects prostate cancer: a two-sample Mendelian randomization.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Benign prostate hyperplasia (BPH) and prostate cancer (PCa) share several similarities, including androgen dependency and parallel increases in prevalence with age. Although PCa lags by 15-20 years, no causal association has been identified between BPH and PCa. To investigate the potential causal links between BPH and PCa, this study was performed in a two-sample Mendelian randomization (MR) design. Methods: We retrieved single-nucleotide polymorphisms (SNPs) associated with BPH from genome-wide association studies (GWAS), which were obtained from the Integrative Epidemiology Unit database, and conducted a two-sample MR analysis to explore the causal relationship between BPH and PCa. The exposure dataset included 13,118 BPH cases and 72,799 controls, while the outcome dataset comprised 9,132 PCa cases and 173,493 controls, all of European ancestry. Four SNPs were selected as instrumental variables (IVs) after stringent filtering for linkage disequilibrium and potential confounding factors. The causal effect was estimated using the inverse-variance-weighted (IVW) method, supplemented by sensitivity analyses to assess heterogeneity and pleiotropy. Results: The IVW analysis revealed that genetically predicted BPH was causally associated with a 1.02-fold increased risk of PCa [95% confidence interval (CI): 1.0076-1.0286, P<0.001]. Sensitivity analyses, including MR-Egger regression and leave-one-out analysis, confirmed the robustness of these findings, with no significant heterogeneity or pleiotropy detected. Conclusions: This study provides genetic evidence supporting a causal relationship between BPH and an increased risk of PCa. These findings suggest that BPH may contribute to the development of PCa, potentially guiding future clinical practices in screening, diagnosis, and treatment strategies for BPH patients to mitigate PCa risk. Further validation in diverse populations and clinical studies is warranted to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.